Hims & Hers vs Roche

Hims & Hers Securities Class Action Deadline Nov 2, 2026

Robbins Geller Rudman & Dowd LLP announces a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged violations of the Securities Exchange Act. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to seek lead plaintiff appointment. The lawsuit follows an FTC complaint alleging Hims & Hers shared sensitive health information with third-party advertising platforms like Meta and Snap, and misled consumers about billing. The stock dropped nearly 15% upon the FTC news. Lead plaintiff process outlined under the Private Securities Litigation Reform Act.

• FTC filed a lawsuit against Hims & Hers on July 29, 2026, alleging sharing of sensitive health data with advertising platforms.
• Hims & Hers stock declined nearly 15% following the FTC announcement.
• Robbins Geller Rudman & Dowd LLP filed a class action lawsuit (Velanki v. Hims & Hers Health, Inc.) in the Northern District of California.

10-Q Financial Filing Analysis for Hims & Hers (2026-08-10)

Hims & Hers reported Q2 2026 revenue of $753.2 million, up 38% year-over-year, and six-month revenue of $1.36 billion (+20% YoY), driven by strong expansion in the Hers brand and international growth from acquisitions including Eucalyptus. However, the company experienced a GAAP net loss of $86.3 million for Q2 2026 (compared to net income of $42.5 million in Q2 2025), primarily impacted by a strategic transition in its U.S. GLP-1 weight loss business, non-recurring restructuring charges, increased fulfillment costs from shorter shipping cadences, and a $60 million FTC legal contingency accrual.

• Q2 2026 total revenue reached $753.21 million (+38% YoY) with ending subscribers expanding 19% YoY to 2.89 million.
• GAAP net loss was $86.29 million for Q2 2026, down from net income of $42.51 million in Q2 2025, while Adjusted EBITDA stood at $60.32 million.
• Recorded a $60.0 million legal contingency accrual related to an FTC and multi-state consumer protection lawsuit regarding subscription and cancellation practices.

Hims & Hers Securities Fraud Class Action Filed

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) in the U.S. District Court for the Northern District of California. The suit alleges the telehealth company disclosed sensitive health information to third-party advertising platforms, including Snap and Meta (Facebook), without proper consent, and misled consumers about billing practices. The FTC filed a related lawsuit on July 29, 2026, causing the stock to drop 14.73% to $25.00. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to apply as lead plaintiff. The case, Velanki v. Hims & Hers Health, Inc. et al., is being publicized by law firms including Kahn Swick & Foti, Kessler Topaz Meltzer & Check, and the Law Offices of Howard G. Smith.

• FTC sued Hims & Hers for sharing sensitive health data with advertising platforms (Snap, Meta) and deceptive billing practices.
• Hims & Hers stock dropped $4.32 (14.73%) to $25.00 on July 29, 2026.
• Class action lawsuit filed; lead plaintiff deadline is November 2, 2026.

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.